Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
0.8097
-0.0060 (-0.74%)
At close: Oct 2, 2026, 4:00 PM EDT
0.8140
+0.0043 (0.53%)
After-hours: Oct 2, 2026, 7:38 PM EDT
Milestone Pharmaceuticals Employees
Milestone Pharmaceuticals had 38 employees as of December 31, 2025. The number of employees increased by 5 or 15.15% compared to the previous year.
Employees
38
Change (1Y)
5
Growth (1Y)
15.15%
Revenue / Employee
$61,658
Profits / Employee
-$2,210,816
Market Cap
114.10M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 38 | 5 | 15.15% |
| Dec 31, 2024 | 33 | -14 | -29.79% |
| Dec 31, 2023 | 47 | 8 | 20.51% |
| Dec 31, 2022 | 39 | 10 | 34.48% |
| Dec 31, 2021 | 29 | 1 | 3.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Seer, Inc. | 124 |
| Cibus | 118 |
| Inovio Pharmaceuticals | 112 |
| Immunic | 100 |
| Rani Therapeutics Holdings | 71 |
| Neumora Therapeutics | 63 |
| Vivani Medical | 42 |
MIST News
- 8 days ago - Milestone announces Montreal Heart Institute enrolled first patient - TheFly
- 8 days ago - Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR - GlobeNewsWire
- 17 days ago - Milestone Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 24 days ago - Milestone Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - Milestone Pharmaceuticals announces NMPA approval of etripamil for PSVT - TheFly
- 4 weeks ago - Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States - GlobeNewsWire
- 4 weeks ago - Milestone Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes - GlobeNewsWire